C Horton

2.8k total citations
79 papers, 2.1k citations indexed

About

C Horton is a scholar working on Hematology, Oncology and Mechanical Engineering. According to data from OpenAlex, C Horton has authored 79 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Hematology, 26 papers in Oncology and 19 papers in Mechanical Engineering. Recurrent topics in C Horton's work include Hematopoietic Stem Cell Transplantation (30 papers), Multiple Myeloma Research and Treatments (22 papers) and Microstructure and mechanical properties (13 papers). C Horton is often cited by papers focused on Hematopoietic Stem Cell Transplantation (30 papers), Multiple Myeloma Research and Treatments (22 papers) and Microstructure and mechanical properties (13 papers). C Horton collaborates with scholars based in United Kingdom, United States and India. C Horton's co-authors include Seema Singhal, R Powles, Jayesh Mehta, J Treleaven, Bhawna Sirohi, J Treleaven, Samar Kulkarni, Diana Tait, J. M. Silcock and Radovan Sašo and has published in prestigious journals such as The Lancet, Blood and British Journal of Cancer.

In The Last Decade

C Horton

78 papers receiving 2.0k citations

Peers

Countries citing papers authored by C Horton

Since Specialization

Citations

This map shows the geographic impact of C Horton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C Horton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C Horton more than expected).

Fields of papers citing papers by C Horton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C Horton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C Horton. The network helps show where C Horton may publish in the future.

Co-authorship network of co-authors of C Horton

This figure shows the co-authorship network connecting the top 25 collaborators of C Horton. A scholar is included among the top collaborators of C Horton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C Horton. C Horton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-α2b in patients with multiple myeloma maintained on a steady dose of interferon-α2b 2007 ·Annals of Oncology ·Bhawna Sirohi, R Powles, Dana J. Lawrence, J Treleaven, S Kulkarni, Alexandra Léary, Charles M. Rudin, C Horton, Gareth J. Morgan	19
2	The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide – vincristine – doxorubicin – methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis 2006 ·Leukemia & lymphoma ·Ping Wu, Faith E. Davies, C Horton, Matthew Jenner, (unknown), Caroline Alvares, Radovan Sašo, (unknown), (unknown), Jennifer Treleaven, Michael Potter, Mark Ethell, Gareth J. Morgan	33
3	Long‐term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high‐dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments 2005 ·British Journal of Haematology ·Caroline Alvares, Faith E. Davies, C Horton, Gita Patel, R Powles, Bhawna Sirohi, (unknown), Alex Gatt, Radovan Sašo, Jennifer Treleaven, Claire Dearden, Michael Potter, Mark Ethell, Gareth J. Morgan	32
4	Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria 2001 ·Bone Marrow Transplantation ·Bhawna Sirohi, R Powles, S Kulkarni, Charles M. Rudin, Radovan Sašo, Rohit Lal, Seema Singhal, Jayesh Mehta, C Horton, J Treleaven	14
5	Glomerular filtration rate prior to high-dose melphalan 200 mg/m2as a surrogate marker of outcome in patients with myeloma 2001 ·British Journal of Cancer ·Bhawna Sirohi, R Powles, S Kulkarni, Charles M. Rudin, Radovan Sašo, Anne Rigg, C Horton, Seema Singhal, Jayesh Mehta, J Treleaven	28
6	Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial 2000 ·The Lancet ·R Powles, Jayesh Mehta, Samar Kulkarni, J Treleaven, Barbara C. Millar, (unknown), V Shepherd, A. J. Rowland, Bhawna Sirohi, Diana Tait, C Horton, S. G. Long, Seema Singhal	268
7	A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 106 CD34+ cells/kg be considered the minimum threshold? 2000 ·Bone Marrow Transplantation ·Seema Singhal, R Powles, J Treleaven, S Kulkarni, Bhawna Sirohi, C Horton, B. C. Millar, V Shepherd, Diana Tait, Radovan Sašo, A. J. Rowland, S. G. Long, Jayesh Mehta	85
8	Melphalan/TBI is not more carcinogenic than cyclophosphamide/TBI for transplant conditioning: follow-up of 725 patients from a single centre over a period of 26 years 2000 ·Bone Marrow Transplantation ·S Kulkarni, R Powles, J Treleaven, Seema Singhal, C Horton, Bhawna Sirohi, (unknown), Diana Tait, Radovan Sašo, Sally Killick, Ross Pinkerton, Ayad Atra, S Meller, Minesh P. Mehta	17
9	The role of autologous transplantation in patients with multiple myeloma aged 65 years and over 2000 ·Bone Marrow Transplantation ·Bhawna Sirohi, R Powles, J Treleaven, Paul N. Mainwaring, S Kulkarni, H. Pandha, Niyati Bhagwati, C Horton, Seema Singhal, Jayesh Mehta	86
10	Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation 2000 ·Bone Marrow Transplantation ·Seema Singhal, R Powles, S Kulkarni, J Treleaven, Bhawna Sirohi, B. C. Millar, V Shepherd, Radovan Sašo, A. J. Rowland, S. G. Long, Sandra Cabral, C Horton, Jayesh Mehta	36
11	Long-Term Outcome of Adult Acute Leukemia Patients Who Are Alive and Well Two Years After Allogeneic Bone Marrow Transplantation from an HLA-Identical Sibling 1999 ·Leukemia & lymphoma ·(unknown), R Powles, J Treleaven, Samar Kulkarni, C Horton, Jayesh Mehta	12
12	Long-term outcome of adult acute leukemia patients who are alive and well 2 years after autologous blood or marrow transplantation 1999 ·Bone Marrow Transplantation ·Seema Singhal, R Powles, J Treleaven, S Kulkarni, C Horton, Jayesh Mehta	7
13	Thalidomide in GVHD - S anti-GVHD effect separable from the antiangiogenesis? 1998 ·Blood ·Shashikant Kulkarni, R Powles, Jayesh Mehta, C Horton, J Treleaven, S Meller, Ayad Atra, CR Pinkerton, Sandeep K. Singhal	4
14	Second cancers after non-autologous bone marrow transplantation for hematologic malignancies 1998 ·British Journal of Haematology ·(unknown), R Powles, Seema Singhal, Minesh P. Mehta, J Treleaven, C Horton, (unknown), CR Pinkerton, Ayad Atra, Diana Tait	1
15	Thalidomide is very effective for chronic GVHD but has no activity in acute GVHD. 1997 ·Blood ·Shashikant Kulkarni, R Powles, Jayesh Mehta, C Horton, J Treleaven, S Meller, Ayad Atra, CR Pinkerton, Sandeep K. Singhal	2
16	Cytomegaloviremia after autografting for leukemia: clinical significance and lack of effect on engraftment 1997 ·Leukemia ·Seema Singhal, R Powles, J Treleaven, C Horton, CR Pinkerton, S Meller, Jayesh Mehta	8
17	Early identification of patients at risk of death due to infections, hemorrhage, or graft failure after allogeneic bone marrow transplantation on the basis of the leukocyte counts 1997 ·Bone Marrow Transplantation ·Jayesh Mehta, R Powles, Seema Singhal, C Horton, Gary Middleton, Timothy Eisen, S Meller, CR Pinkerton, J Treleaven	26
18	Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma 1997 ·British Journal of Cancer ·Noopur Raje, R Powles, C Horton, B. C. Millar, V Shepherd, Gary Middleton, S Kulkarni, Timothy Eisen, Jayesh Mehta, Seema Singhal, J Treleaven	18
19	Long-Term Safety of GM-CSF (Molgramostim) Administration After Allogeneic Bone Marrow Transplantation for Hematologic Malignancies: Five-Year Follow-Up of a Double-Blind Randomized Placebo-Controlled Study 1997 ·Leukemia & lymphoma ·Seema Singhal, R Powles, Jennie Treleaven, C Horton, Jayesh Mehta	8
20	Comparison of Interferon Tolerance after Autologous Bone Marrow or Peripheral Blood Stem Cell Transplants for Myeloma Patients who have Responded to Induction Therapy 1996 ·Leukemia & lymphoma ·R Powles, Noopur Raje, C Horton, Jayesh Mehta, Seema Singhal, Tamas Hickish, C. Viner, (unknown), J Treleaven, David Cunningham	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact